428 related articles for article (PubMed ID: 18436089)
1. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session.
Brunet P; Simon N; Opris A; Faure V; Lorec-Penet AM; Portugal H; Dussol B; Berland Y
Am J Kidney Dis; 2008 May; 51(5):789-95. PubMed ID: 18436089
[TBL] [Abstract][Full Text] [Related]
2. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study.
Klingel R; Schwarting A; Lotz J; Eckert M; Hohmann V; Hafner G
Kidney Blood Press Res; 2004; 27(4):211-7. PubMed ID: 15273423
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of coagulation and anti-Xa factor when using a heparin-coated AN69ST® dialyser.
Sánchez-Canel JJ; Pons-Prades R; Salvetti ML; Seores A; Vázquez M; Pérez-Alba A; Tamarit E; Calvo-Gordo C; Villatoro J
Nefrologia; 2012; 32(5):605-12. PubMed ID: 23013946
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
[TBL] [Abstract][Full Text] [Related]
6. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.
Lavaud S; Canivet E; Wuillai A; Maheut H; Randoux C; Bonnet JM; Renaux JL; Chanard J
Nephrol Dial Transplant; 2003 Oct; 18(10):2097-104. PubMed ID: 13679486
[TBL] [Abstract][Full Text] [Related]
7. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?].
Sefer S; Kes P; Raić B; Heinrich B; Degoricija V; Szavits-Nossan J
Acta Med Croatica; 2006 Jun; 60(3):281-5. PubMed ID: 16933844
[TBL] [Abstract][Full Text] [Related]
8. Heparin elimination and hemostasis in hemodialysis.
Wilhelmsson S; Lins LE
Clin Nephrol; 1984 Dec; 22(6):303-6. PubMed ID: 6525772
[TBL] [Abstract][Full Text] [Related]
9. Elevated hepatocyte growth factor levels at the beginning of high-flux hemodialysis are due to heparin administration.
Christidou F; Bamichas G; Galaktidou G; Fragidis S; Gionanlis L; Frangia T; Bischiniotis T; Sombolos K
Ren Fail; 2008; 30(9):861-4. PubMed ID: 18925524
[TBL] [Abstract][Full Text] [Related]
10. [Use of fragmin in program hemodialysis of patients with terminal chronic renal failure].
Kozlova TV; Shilo VIu; Denisov AIu
Klin Med (Mosk); 2005; 83(9):45-9. PubMed ID: 16279040
[TBL] [Abstract][Full Text] [Related]
11. Optimization of heparin anticoagulation for hemodialysis.
Davenport A
Hemodial Int; 2011 Oct; 15 Suppl 1():S43-8. PubMed ID: 22093600
[TBL] [Abstract][Full Text] [Related]
12. A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients.
Perry SL; O'Shea SI; Byrne S; Szczech LA; Ortel TL
Thromb Haemost; 2006 Dec; 96(6):750-5. PubMed ID: 17139369
[TBL] [Abstract][Full Text] [Related]
13. A low molecular weight heparin ("fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin.
Anastassiades E; Lane DA; Ireland H; Flynn A; Curtis JR
Clin Nephrol; 1989 Dec; 32(6):290-6. PubMed ID: 2558829
[TBL] [Abstract][Full Text] [Related]
14. Heparin-grafted dialysis membrane allows minimal systemic anticoagulation in regular hemodialysis patients: a prospective proof-of-concept study.
Kessler M; Gangemi C; Gutierrez Martones A; Lacombe JL; Krier-Coudert MJ; Galland R; Kielstein JT; Moureau F; Loughraieb N
Hemodial Int; 2013 Apr; 17(2):282-93. PubMed ID: 22925178
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session: the impact of the administered dose.
Fourtounas C
Am J Kidney Dis; 2008 Oct; 52(4):805-6; author reply 806-7. PubMed ID: 18805352
[No Abstract] [Full Text] [Related]
16. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study).
Imberti D; Legnani C; Baldini E; Cini M; Nicolini A; Guerra M; De Paoli M; Zanardi A; Palareti G
Thromb Res; 2009 Dec; 124(6):667-71. PubMed ID: 19482341
[TBL] [Abstract][Full Text] [Related]
17. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
Kruse MW; Lee JJ
Am Heart J; 2004 Oct; 148(4):582-9. PubMed ID: 15459586
[TBL] [Abstract][Full Text] [Related]
18. The effect of r-hirudin vs. heparin on blood-membrane interactions during hemodialysis.
van Wyk V; Badenhorst PN; Kotzé HF
Clin Nephrol; 1997 Dec; 48(6):381-7. PubMed ID: 9438098
[TBL] [Abstract][Full Text] [Related]
19. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
Oldgren J; Johnston N; Siegbahn A
Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
Boneu B; Navarro C; Cambus JP; Caplain H; d'Azemar P; Necciari J; Duret JP; Gaud C; Sié P
Thromb Haemost; 1998 Feb; 79(2):338-41. PubMed ID: 9493587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
